PXL770
Rare Metabolic Diseases (e.g., ADPKD)
Phase 2aDivested (Sold to Scynexis)
Key Facts
Indication
Rare Metabolic Diseases (e.g., ADPKD)
Phase
Phase 2a
Status
Divested (Sold to Scynexis)
Company
About Poxel
Poxel is a French biotech focused on developing first-in-class treatments for metabolic diseases by targeting mitochondrial bioenergetics. Its strategy leverages two core platforms—direct AMPK activation and optimized thiazolidinediones (TZDs)—to build a pipeline led by mid-stage NASH candidates PXL065 and PXL770. The company has transitioned to a revenue-generating entity through royalties from its partnered drug, Imeglimin, in Japan, but operates under a court-validated financial recovery plan, highlighting significant capital constraints alongside its clinical progress.
View full company profile